Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Oesophagus or Gastric

Trial Profile

Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Oesophagus or Gastric

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jan 2016 Status changed from recruiting to completed, according to results presented at the 2016 Gastrointestinal Cancers Symposium.
    • 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 31 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top